Irritable Bowel Syndrome

Data show nearly 1 in 10 patients with IBS-D in study were identified with SID.

Data show clinically meaningful improvement in IBDQ score and MCS score in patients treated with UST.

Data show a 23.5% increase in influenza vaccination rates.

Data show biologic therapy was not associated with ICU admission or death due to infection.

Linaclotide has been marketed as LINZESS to treat irritable bowel syndrome with constipation.

In data presented at ACG, investigators found a link between sex, lower BMI, and the development of irritable bowel syndrome in patients following a c. diff infection.

New data shows that clinical isolates of C. difficile are variably affected by manuka honey in terms of growth inhibition and bactericidal activity.

TLR9 activation shows potential as a target for ulcerative colitis and warrants further testing.

There is a higher prevalence of IBS found in women than men.

Patients in the multidisciplinary-care group were more likely to experience a 50% or higher reduction in all Gastrointestinal Symptom Severity Index symptom clusters than the patients who were in the standard-care group.

New recommendations support the use of probiotics for preterm and low birthweight infants to prevent mortality and necrotizing enterocolitis.

A new analysis of data from Northwestern Medicine found some chronic inflammatory diseases were associated with a 7-fold increase in risk of heart failure.

In an international survey, investigators discover women are more likely to suffer from a FGID than men.

In a new study, investigators discover fewer adverse events in patients taking 1 × 109 non-viable B bifidum HI-MIMBb75 cells than for patients taking a placebo.

The most common reason IBS patients discontinue treatment is a loss of prescription drug coverage.

A 28-day patient log of gastrointestinal symptoms, stool consistency, psychological distress, and extraintestinal pain ratings informs investigators on the significance of markers.

In a new study, investigators examine whether a low FODMAP diet could be beneficial for patients suffering from quiescent IBD.

In the last decade, investigators have put an emphasis on better disease monitoring for digestive diseases. The result has been better patient outcomes.

William Sandborn, MD, chief of the division of gastroenterology at University of California, San Diego, shares updates from ACG 2019 in the field of gastroenterology.

Stephen B. Hanauer, MD, discusses areas of unmet need in gastroenterology and shares what news made a splash at ACG 2019.

Brooks Cash, MD, delivers his take on areas of unmet need within the gastroenterology field.

From baseline to 12 weeks, all participants demonstrated a significant reduction in total percentage of abnormal bowel movements, overall IBS Symptom Severity Score, abdominal pain and bloating severity, and an improvement in health-related quality of life.

Ustekinumab (Stelara) has received approval from the US Food and Drug Administration for the treatment of moderate to severely active ulcerative colitis in adults.

The AGA-approved guidelines call for a variety of different testing to better diagnose IBS-D in adults.

The FDA-approved drug targets IBS-C patients by increasing bowel movements, while lowering abdominal pain.

In a new multivariable regression study, investigators link depression with a lack of social support and increased IBD activity.

Investigators found positive results when examining the safety and efficacy of filgotinib in the FINCH 2 phase 3 clinical trial.